Biopharma companies must weigh the operational complexity of continuous bioprocess against its potential productivity gains.
Learn about emerging standards for biologics that support efficient development and regulatory review, regulatory convergence ...
If you have an account with us, sign in to persist your opt-out. If you do not have an account, you may opt-out of the ...
BPI Contributor Will Miller ...
BioProcess International reviews key biotech trends from the first half of 2026, including US onshoring, China's biologics ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Earlier this month, data analytics and consulting firm GlobalData released a report citing an increasingly widening ...
New York invests $65M in biotech with new clinical trial consortium and Biogenesis Park to compete with Boston, San Francisco ...
Beyond Installation, Operational, and Performance Qualifications: A Risk-Based Validation Framework for AI-Driven Software in ...
AstraZeneca reports 88% emissions cut since 2015, crediting AI for accelerating drug discovery while embedding sustainability ...
Clinigen's Jules Shale discusses navigating complex logistics to deliver life-saving therapies and the rewarding human ...
Sivakumar Kalidoss, BPI contributor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results